» Articles » PMID: 39778878

Quantitative Analysis of Nonhistone Lysine Methylation Sites and Lysine Demethylases in Breast Cancer Cell Lines

Overview
Journal J Proteome Res
Date 2025 Jan 8
PMID 39778878
Authors
Affiliations
Soon will be listed here.
Abstract

Growing evidence shows that lysine methylation is a widespread protein post-translational modification (PTM) that regulates protein function on histone and nonhistone proteins. Numerous studies have demonstrated that the dysregulation of lysine methylation mediators contributes to cancer growth and chemotherapeutic resistance. While changes in histone methylation are well-documented with extensive analytical techniques available, there is a lack of high-throughput methods to reproducibly quantify changes in the abundances of the mediators of lysine methylation and nonhistone lysine methylation (Kme) simultaneously across multiple samples. Recent studies by our group and others have demonstrated that antibody enrichment is not required to detect lysine methylation, prompting us to investigate the use of tandem mass tag (TMT) labeling for global Kme quantification without antibody enrichment in four different breast cancer cell lines (MCF-7, MDA-MB-231, HCC1806, and MCF10A). To improve the quantification of KDMs, we incorporated a lysine demethylase (KDM) isobaric trigger channel, which enabled 96% of all KDMs to be quantified while simultaneously quantifying 326 Kme sites. Overall, 142 differentially abundant Kme sites and eight differentially abundant KDMs were identified among the four cell lines, revealing cell line-specific patterning.

References
1.
Ong S, Mittler G, Mann M . Identifying and quantifying in vivo methylation sites by heavy methyl SILAC. Nat Methods. 2005; 1(2):119-26. DOI: 10.1038/nmeth715. View

2.
Holm K, Grabau D, Lovgren K, Aradottir S, Gruvberger-Saal S, Howlin J . Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes. Mol Oncol. 2012; 6(5):494-506. PMC: 5528390. DOI: 10.1016/j.molonc.2012.06.002. View

3.
Grimes M, Hall B, Foltz L, Levy T, Rikova K, Gaiser J . Integration of protein phosphorylation, acetylation, and methylation data sets to outline lung cancer signaling networks. Sci Signal. 2018; 11(531). PMC: 6822907. DOI: 10.1126/scisignal.aaq1087. View

4.
Zhou M, Pitta Venkata P, Viswanadhapalli S, Palacios B, Alejo S, Chen Y . KDM1A inhibition is effective in reducing stemness and treating triple negative breast cancer. Breast Cancer Res Treat. 2020; 185(2):343-357. DOI: 10.1007/s10549-020-05963-1. View

5.
Kung C, Cottrell K, Ryu S, Bramel E, Kladney R, Bao E . Evaluating the therapeutic potential of ADAR1 inhibition for triple-negative breast cancer. Oncogene. 2020; 40(1):189-202. PMC: 7796950. DOI: 10.1038/s41388-020-01515-5. View